Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: A forgotten pearl

被引:29
作者
Thiele, J.
Kvasnicka, H. M.
Vardiman, J.
机构
[1] Univ Cologne, Inst Pathol, D-50924 Cologne, Germany
[2] Univ Chicago, Med Ctr, Dept Pathol, Chicago, IL 60637 USA
关键词
histological staging; dynamics; chronic myelogenous leukemia; polycythemia vera; chronic myelofibrosis; essential thrombocythemia; bone marrow biopsies;
D O I
10.1016/j.beha.2005.07.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Histopathology of bone marrow (BM) biopsies plays a crucial role in the interdisciplinary approach to diagnosis and classification of chronic myeloproliferative disorders (CMPDs). Based on careful clinicopathologic studies, BM features are critical determinants that help to predict overall prognosis, to detect complications such as progression to myelofibrosis and blast crisis, and to assess therapy-related changes. A systematic evaluation of BM histopathology allows an objective identification of cases of (true) essential thrombocythemia (ET) and their separation from (false) ET which often is the prodromal stage of chronic idiopathic myelofibrosis (CIMF). By follow-up examinations that include BM biopsies, the progression of the disease process is unveiled, which is especially important for patients with initial (early) polycythemia vera and prefibrotic CIMF that may require a different therapeutic approach than the full-blown stages. In conclusion, BM biopsy should be considered as major diagnostic tool for evaluation and follow-up of patients enrolled in prospective studies.
引用
收藏
页码:413 / 437
页数:25
相关论文
共 104 条
[1]  
Annaloro C, 1999, HAEMATOLOGICA, V84, P17
[2]  
Arora B, 2004, HAEMATOLOGICA, V89, P1454
[3]   The role of interferon-α in the treatment of idiopathic myelofibrosis [J].
Bachleitner-Hofmann, T ;
Gisslinger, H .
ANNALS OF HEMATOLOGY, 1999, 78 (12) :533-538
[4]   Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines [J].
Barosi, G .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2954-2970
[5]  
BARTL R, 1993, EUR J HAEMATOL, V50, P41
[6]   Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis [J].
Beham-Schmid, C ;
Apfelbeck, U ;
Sill, H ;
Tsybrovsky, O ;
Höfler, G ;
Haas, OA ;
Linkesch, W .
BLOOD, 2002, 99 (01) :381-383
[7]  
BILGRAMI S, 1995, SEMIN ONCOL, V22, P307
[8]  
Birgegård G, 2004, HAEMATOLOGICA, V89, P520
[9]   Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial [J].
Buesche, G ;
Hehlmann, R ;
Hecker, H ;
Heimpel, H ;
Heinze, B ;
Schmeil, A ;
Pfirrmann, M ;
Gomez, G ;
Tobler, A ;
Herrmann, H ;
Kappler, M ;
Hasford, J ;
Buhr, T ;
Kreipe, HH ;
Georgii, A .
LEUKEMIA, 2003, 17 (12) :2444-2453
[10]   Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia [J].
Bueso-Ramos, CE ;
Cortes, J ;
Talpaz, M ;
O'Brien, S ;
Giles, F ;
Rios, MB ;
Medeiros, LJ ;
Kantarjian, H .
CANCER, 2004, 101 (02) :332-336